Log in
NASDAQ:ATRC

AtriCure Competitors

$43.24
+0.78 (+1.84 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$42.15
Now: $43.24
$43.84
50-Day Range
$34.56
MA: $38.92
$42.84
52-Week Range
$23.17
Now: $43.24
$51.76
Volume379,643 shs
Average Volume412,681 shs
Market Capitalization$1.95 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92

Competitors

AtriCure (NASDAQ:ATRC) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying ATRC stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to AtriCure, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

Abbott Laboratories (NYSE:ABT) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Profitability

This table compares Abbott Laboratories and AtriCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
AtriCure-21.74%-14.83%-7.77%

Risk & Volatility

Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.

Institutional and Insider Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 5.8% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Abbott Laboratories and AtriCure's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.07$3.69 billion$3.2433.73
AtriCure$230.81 million8.43$-35,190,000.00($1.07)-40.41

Abbott Laboratories has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Abbott Laboratories and AtriCure, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories141302.67
AtriCure00703.00

Abbott Laboratories presently has a consensus price target of $115.3750, indicating a potential upside of 5.59%. AtriCure has a consensus price target of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Abbott Laboratories.

Summary

Abbott Laboratories beats AtriCure on 8 of the 14 factors compared between the two stocks.

Medtronic (NYSE:MDT) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Medtronic and AtriCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic15.80%10.47%5.80%
AtriCure-21.74%-14.83%-7.77%

Volatility and Risk

Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

79.9% of Medtronic shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 0.5% of Medtronic shares are held by company insiders. Comparatively, 5.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Medtronic and AtriCure's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.16$4.79 billion$4.5924.18
AtriCure$230.81 million8.43$-35,190,000.00($1.07)-40.41

Medtronic has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Medtronic and AtriCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic132012.84
AtriCure00703.00

Medtronic presently has a consensus target price of $118.1538, indicating a potential upside of 6.47%. AtriCure has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Medtronic.

Summary

Medtronic beats AtriCure on 9 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Stryker and AtriCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker11.38%20.53%8.89%
AtriCure-21.74%-14.83%-7.77%

Volatility and Risk

Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

71.0% of Stryker shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 5.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Stryker and AtriCure's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion5.88$2.08 billion$8.2628.21
AtriCure$230.81 million8.43$-35,190,000.00($1.07)-40.41

Stryker has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Stryker and AtriCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker291512.56
AtriCure00703.00

Stryker presently has a consensus target price of $221.44, indicating a potential downside of 4.97%. AtriCure has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Stryker.

Summary

Stryker beats AtriCure on 10 of the 15 factors compared between the two stocks.

Intuitive Surgical (NASDAQ:ISRG) and AtriCure (NASDAQ:ATRC) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

Profitability

This table compares Intuitive Surgical and AtriCure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intuitive Surgical24.45%12.08%10.44%
AtriCure-21.74%-14.83%-7.77%

Volatility and Risk

Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, AtriCure has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

86.9% of Intuitive Surgical shares are held by institutional investors. Comparatively, 88.6% of AtriCure shares are held by institutional investors. 1.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 5.8% of AtriCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Intuitive Surgical and AtriCure's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intuitive Surgical$4.48 billion18.87$1.38 billion$9.9572.27
AtriCure$230.81 million8.43$-35,190,000.00($1.07)-40.41

Intuitive Surgical has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Intuitive Surgical and AtriCure, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intuitive Surgical371202.41
AtriCure00703.00

Intuitive Surgical presently has a consensus target price of $718.2778, indicating a potential downside of 0.11%. AtriCure has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Given AtriCure's stronger consensus rating and higher possible upside, analysts plainly believe AtriCure is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats AtriCure on 10 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and Becton, Dickinson and (NYSE:BDX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

88.6% of AtriCure shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares AtriCure and Becton, Dickinson and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$230.81 million8.43$-35,190,000.00($1.07)-40.41
Becton, Dickinson and$17.12 billion3.87$874 million$10.2022.40

Becton, Dickinson and has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for AtriCure and Becton, Dickinson and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtriCure00703.00
Becton, Dickinson and07712.60

AtriCure currently has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Becton, Dickinson and has a consensus target price of $280.2857, indicating a potential upside of 22.67%. Given AtriCure's stronger consensus rating and higher possible upside, equities analysts clearly believe AtriCure is more favorable than Becton, Dickinson and.

Profitability

This table compares AtriCure and Becton, Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtriCure-21.74%-14.83%-7.77%
Becton, Dickinson and5.11%13.30%5.60%

Volatility and Risk

AtriCure has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Summary

Becton, Dickinson and beats AtriCure on 8 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and Edwards Lifesciences (NYSE:EW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

88.6% of AtriCure shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 5.8% of AtriCure shares are owned by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares AtriCure and Edwards Lifesciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$230.81 million8.43$-35,190,000.00($1.07)-40.41
Edwards Lifesciences$4.35 billion12.14$1.05 billion$1.8645.54

Edwards Lifesciences has higher revenue and earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for AtriCure and Edwards Lifesciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtriCure00703.00
Edwards Lifesciences251302.55

AtriCure currently has a consensus target price of $53.2857, indicating a potential upside of 23.23%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given AtriCure's stronger consensus rating and higher possible upside, equities analysts clearly believe AtriCure is more favorable than Edwards Lifesciences.

Profitability

This table compares AtriCure and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtriCure-21.74%-14.83%-7.77%
Edwards Lifesciences18.18%29.00%18.10%

Volatility and Risk

AtriCure has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Summary

Edwards Lifesciences beats AtriCure on 9 of the 13 factors compared between the two stocks.


AtriCure Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.2$109.27+1.5%$193.67 billion$31.90 billion57.82
Medtronic logo
MDT
Medtronic
2.7$110.97+0.7%$149.17 billion$28.91 billion33.94
Stryker logo
SYK
Stryker
2.0$233.01+0.1%$87.56 billion$14.88 billion55.35
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$719.05+1.6%$84.53 billion$4.48 billion81.90
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.0$228.48+1.5%$66.23 billion$17.12 billion83.69Increase in Short Interest
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$84.70+0.2%$52.79 billion$4.35 billion67.76
Boston Scientific logo
BSX
Boston Scientific
2.4$33.33+1.1%$47.73 billion$10.74 billion12.77
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$459.79+1.0%$39.22 billion$2.41 billion80.10
Baxter International logo
BAX
Baxter International
2.3$75.77+1.6%$38.70 billion$11.36 billion43.05Increase in Short Interest
DexCom logo
DXCM
DexCom
2.1$321.09+1.6%$30.83 billion$1.48 billion132.68
ResMed logo
RMD
ResMed
1.7$209.57+0.7%$30.37 billion$2.96 billion49.08
Insulet logo
PODD
Insulet
1.3$265.89+0.2%$17.53 billion$738.20 million949.64
Hologic logo
HOLX
Hologic
1.9$68.07+1.4%$17.49 billion$3.37 billion16.21Analyst Downgrade
Teleflex logo
TFX
Teleflex
1.8$373.14+0.7%$17.38 billion$2.60 billion36.73
STERIS logo
STE
STERIS
1.9$189.09+3.5%$16.13 billion$3.03 billion39.31
Varian Medical Systems logo
VAR
Varian Medical Systems
1.4$173.50+0.0%$15.78 billion$3.23 billion56.51
Masimo logo
MASI
Masimo
1.6$245.50+1.0%$13.52 billion$937.84 million63.77
Abiomed logo
ABMD
Abiomed
1.5$266.43+0.7%$12.04 billion$840.88 million58.56
Hill-Rom logo
HRC
Hill-Rom
1.9$97.55+0.1%$6.52 billion$2.91 billion31.47Unusual Options Activity
Globus Medical logo
GMED
Globus Medical
1.5$58.47+1.1%$5.77 billion$785.37 million63.55
Integra LifeSciences logo
IART
Integra LifeSciences
1.4$54.78+0.5%$4.62 billion$1.52 billion81.76
Wright Medical Group logo
WMGI
Wright Medical Group
1.1$29.98+0.0%$3.90 billion$920.90 million-28.28
CONMED logo
CNMD
CONMED
1.5$103.32+2.0%$2.96 billion$955.10 million108.76Dividend Announcement
Insider Selling
NuVasive logo
NUVA
NuVasive
1.8$47.18+2.3%$2.42 billion$1.17 billion-214.45
Integer logo
ITGR
Integer
2.2$71.37+2.1%$2.35 billion$1.26 billion32.44
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$34.90+1.2%$1.40 billion$236.54 million-52.88Analyst Downgrade
Alphatec logo
ATEC
Alphatec
1.2$10.55+2.4%$827.38 million$113.43 million-9.59
CryoLife logo
CRY
CryoLife
2.1$20.87+4.0%$810.95 million$276.22 million-54.92
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$37.14+2.7%$718.07 million$459.95 million30.95
Surmodics logo
SRDX
Surmodics
1.5$38.12+2.4%$518.66 million$100.08 million68.07
AngioDynamics logo
ANGO
AngioDynamics
1.5$12.52+0.6%$475.17 million$264.16 million-2.83
Accuray logo
ARAY
Accuray
2.0$4.40+11.1%$401.61 million$382.93 million31.43High Trading Volume
Unusual Options Activity
Invacare logo
IVC
Invacare
1.4$8.98+1.1%$309.07 million$927.96 million-7.30
Rockwell Medical logo
RMTI
Rockwell Medical
1.3$0.94+1.1%$88.32 million$61.30 million-2.10
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.